Skip to main content
. Author manuscript; available in PMC: 2016 Mar 29.
Published in final edited form as: Gynecol Oncol. 2013 Feb 4;129(2):304–309. doi: 10.1016/j.ygyno.2013.01.025

Figure 1.

Figure 1

Overall survival rates for all patients on the protocol. There was no significant difference in overall survival between the patients with stage I-II disease and those with stage IIIA disease.[5]